NASDAQ:CTSO
Cytosorbents Corporation Stock News
$0.82
+0.122 (+17.40%)
At Close: Jul 02, 2024
CytoSorbents Secures $20 Million Credit Facility
07:00am, Tuesday, 02'nd Jul 2024
PRINCETON, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usin
CytoSorbents to Host its 2024 Virtual Annual Stockholders Meeting
07:00am, Wednesday, 05'th Jun 2024
PRINCETON, N.J., June 05, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usin
B. Riley Weighs in on Cytosorbents Co.’s Q2 2024 Earnings (NASDAQ:CTSO)
01:38am, Monday, 20'th May 2024
Cytosorbents Co. (NASDAQ:CTSO – Free Report) – Equities research analysts at B. Riley dropped their Q2 2024 earnings per share estimates for Cytosorbents in a research note issued on Wedne
Cytosorbents Corporation (CTSO) Q1 2024 Earnings Call Transcript
11:01pm, Thursday, 09'th May 2024
Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2024 Earnings Conference Call May 9, 2024 4:30 PM ET Company Participants Eric Ribner - Investor Relations Phil Chan - Chief Executive Officer Vincent Cappon
CytoSorbents Reports First Quarter 2024 Results
04:17pm, Thursday, 09'th May 2024
Product Sales up a robust 14% over prior year, and a significant 22% sequentially We believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary a
CytoSorbents to Report First Quarter 2024 Operating and Financial Results
07:00am, Friday, 26'th Apr 2024
PRINCETON, N.J., April 26, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi
PRINCETON, N.J., April 17, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
10:24pm, Thursday, 14'th Mar 2024
CytoSorbents Corporation (CTSO) Q4 2023 Earnings Call Transcript
CytoSorbents Reports Fourth Quarter and Full Year 2023 Results
04:39pm, Thursday, 14'th Mar 2024
STAR-T trial results selected for a Breakout Presentation at the American Association of Thoracic Surgery Annual Meeting in late-April 2024 CytoSorbents intends to submit DrugSorb-ATR for regulatory a
CytoSorbents to Report Fiscal 2023 Operating and Financial Results
07:00am, Wednesday, 06'th Mar 2024
PRINCETON, N.J., March 06, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usi
CytoSorbents to Present at the TD Cowen 44th Annual Health Care Conference
07:00am, Thursday, 08'th Feb 2024
PRINCETON, N.J., Feb. 08, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery usin
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
07:40pm, Tuesday, 30'th Jan 2024
NEW YORK , Jan. 30, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are a
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
07:55pm, Monday, 22'nd Jan 2024
NEW YORK , Jan. 22, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are
Groundbreaking Randomized Controlled Trial Reports Excellent Clinical Outcomes Using CytoSorb® Intraoperatively in Heart Transplant Patients
07:15am, Wednesday, 17'th Jan 2024
CytoSorb Blood Purification Results in Significant Decrease in Organ Failure and Dysfunction in Groundbreaking Heart Transplant Randomized Controlled Trial
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Cytosorbents Corporation - CTSO
11:45am, Sunday, 14'th Jan 2024
NEW YORK , Jan. 14, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cytosorbents Corporation ("Cytosorbents" or the "Company") (NASDAQ: CTSO). Such investors are